financetom
Business
financetom
/
Business
/
Uber teams up with May Mobility to launch robotaxis in U.S. cities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Uber teams up with May Mobility to launch robotaxis in U.S. cities
May 25, 2025 11:39 PM

May 1 (Reuters) - Uber Technologies ( UBER ) said on Thursday it will partner with

self-driving technology startup May Mobility to deploy thousands of self-driving vehicles on its

ride-hailing platform across U.S. cities, starting with Arlington, Texas, by late 2025.

This adds to Uber's ( UBER ) growing list of partners for self-driving taxi deployment as it competes

with Lyft ( LYFT ) and EV-maker Tesla in the robotaxi market.

The ride-sharing market leader expanded its partnership with Alphabet's Waymo last

year and signed new deals with China's WeRide ( WRD ) and Avride to strengthen its position in

the burgeoning segment.

Tesla unveiled its Cybercab robotaxi concept in October, with production planned

for 2026 and service launch expected in Austin, Texas this year.

Analysts and industry experts caution that developing self-driving systems face significant

engineering and regulatory challenges.

The U.S. federal government is facilitating the deployment of autonomous vehicles by

expanding exemptions from certain safety requirements while maintaining mandatory incident

reporting.

May Mobility's robotaxis will initially operate with safety drivers before transitioning to

fully autonomous operations.

The Ann Arbor, Michigan-based startup has raised over $380 million from investors including

Toyota ( TM ) and BMW.

May Mobility, which has been operating in Arlington since 2021, will operate U.S.-made

gasoline-electric hybrid Toyota Sienna minivans under the partnership, the companies said.​

May Mobility last year announced a similar collaboration with Lyft ( LYFT ) to deploy self-driving

taxis in Atlanta, Georgia, starting this year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Airship AI Holdings Insider Sold Shares Worth $357,595, According to a Recent SEC Filing
Airship AI Holdings Insider Sold Shares Worth $357,595, According to a Recent SEC Filing
Jun 25, 2025
05:28 PM EDT, 06/25/2025 (MT Newswires) -- Paul M. Allen, President, on June 23, 2025, sold 70,000 shares in Airship AI Holdings ( AISP ) for $357,595. Following the Form 4 filing with the SEC, Allen has control over a total of 51,948 common shares of the company, with 51,948 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1842566/000116169725000192/xslF345X05/form_4.xml ...
DBV Technologies Screens First Subject for Supplemental Safety Study in Peanut Allergic Toddlers
DBV Technologies Screens First Subject for Supplemental Safety Study in Peanut Allergic Toddlers
Jun 25, 2025
05:25 PM EDT, 06/25/2025 (MT Newswires) -- DBV Technologies ( DBVT ) has begun screening subjects for a phase 3 supplemental safety study evaluating the Viaskin Peanut patch in peanut-allergic children aged 1-3. The study will supplement the safety and efficacy data from a separate completed phase 3 study in the same population, the company said late Wednesday. The supplemental...
Vor Biopharma Licenses Autoimmune Drug From RemeGen, Names New CEO
Vor Biopharma Licenses Autoimmune Drug From RemeGen, Names New CEO
Jun 25, 2025
05:29 PM EDT, 06/25/2025 (MT Newswires) -- Vor Biopharma ( VOR ) said late Wednesday it entered a license agreement with RemeGen for global rights, excluding Greater China, to develop and commercialize telitacicept for autoimmune conditions including generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. The company will initially pay RemeGen $125 million, including a $45 million upfront payment...
Copyright 2023-2026 - www.financetom.com All Rights Reserved